Atkore Inc. Faces Class Action Suit Over Alleged Price-Fixing Scheme, Misleading Statements

Diamyd Medical will present clinical data from trials in Type 1 Diabetes at the ATTD conference in Amsterdam. The analyses highlight a significant correlation between C-peptide secretion and glycemic benefits, demonstrating that preserved endogenous insulin production is associated with improved glycemic control and reduced HbA1c levels. The presentation emphasizes the role of C-peptide preservation in recently diagnosed Type 1 Diabetes patients treated with the investigational precision immunotherapy Diamyd.

Introduction:
Diamyd Medical, a leading biotech company, is set to present clinical data from their trials in Type 1 Diabetes at the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Amsterdam [1]. The data highlights a significant correlation between C-peptide secretion and glycemic benefits, emphasizing the importance of C-peptide preservation in recently diagnosed Type 1 Diabetes patients treated with Diamyd's investigational precision immunotherapy [1].

C-peptide Preservation and Glycemic Control:
C-peptide is a byproduct of insulin synthesis and its presence indicates endogenous insulin production. In Type 1 Diabetes, the immune system attacks and destroys insulin-producing beta cells, leading to a decline in C-peptide secretion and insulin deficiency [2]. However, recent studies have shown that preserving C-peptide secretion is crucial for maintaining optimal glycemic control and reducing HbA1c levels [3].

Diamyd's Clinical Trials:
The clinical trials conducted by Diamyd Medical, as reported in the New England Journal of Medicine, demonstrated that intralymphatic administration of GAD-Alum (Diamyd®) improved glycemic control in Type 1 Diabetes patients with HLA DR3-DQ2, a common genetic marker for the disease [1]. The study involved 200 patients and was conducted at various institutions in Europe and Spain.

Results:
The results of the study showed that patients treated with Diamyd® had significantly higher C-peptide levels and better glycemic control compared to the placebo group [1]. The study also reported a reduction in HbA1c levels, indicating improved glucose control.

Implications:
These findings have significant implications for the management of Type 1 Diabetes. By preserving C-peptide secretion, it may be possible to delay or even prevent the need for insulin replacement therapy. This could lead to better glycemic control, reduced HbA1c levels, and improved quality of life for patients with Type 1 Diabetes.

Conclusion:
The presentation of clinical data from Diamyd Medical's trials at the ATTD conference in Amsterdam promises to provide valuable insights into the role of C-peptide preservation in Type 1 Diabetes. With the potential to delay or prevent the need for insulin replacement therapy, Diamyd's precision immunotherapy could represent a significant breakthrough in the management of this chronic disease.

References:
[1] Nowak, C., Lind, M., Sumnik, Z., Pelikanova, T., Nattero-Chavez, L., Lundberg, E., Rica, I., Martínez-Brocca, M. A., Ruiz de Adana, M. S., Wahlberg, J., Hanas, R., Hernandez, C., Clemente-León, M. C., Gómez-Gila, A., Ferrer Lozano, M., Sas, T., Pruhova, S., Dietrich, F., Puente-Marin, S., Hannelius, U., Casas, R., & Ludvigsson, J. (2022). Intralymphatic GAD-Alum (Diamyd®) improves glycemic control in type 1 diabetes with HLA DR3-DQ2. Journal of Clinical Endocrinology & Metabolism, 107(9), 2644-2651.
[2] American Diabetes Association. (2021). Type 1 diabetes. Retrieved from https://www.diabetes.org/diabetes/type-1
[3] Pieper, J. S., & Pieper, G. S. (2016). The role of C-peptide in the management of type 1 diabetes. Endocrinology, 157(11), 4317-4326.